))
Exploring the Transformative Potential of Checkpoint Inhibitors and CAR T-Cells
Archived series ("Inactive feed" status)
When?
This feed was archived on May 11, 2019 03:50 (
Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.
What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.
Manage episode 172227301 series 1302885
Content provided by Clarivate Analytics – Formerly the IP and Science business of Thomson Reuters. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clarivate Analytics – Formerly the IP and Science business of Thomson Reuters or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Cancer immunotherapy research continues to evolve and offers patients a transformative alternative to traditional therapies. Anette Briendl, Senior Science Editor at BioWorld, talks about the current research landscape for immunotherapies. Learn about the challenges and potential of emerging therapies that are being developed, including the importance of checkpoint inhibitors and Car T-cells, to improve patient outcomes and how her work has provided incredible insight into developments in the immuno-oncology space.
8 episodes
Share
